Last reviewed · How we verify
Combination of pimecrolimus and fluticasone
Combination of pimecrolimus and fluticasone is a Topical immunosuppressant and corticosteroid combination Small molecule drug developed by Children's Hospital of Philadelphia. It is currently FDA-approved for Atopic dermatitis in pediatric patients, Inflammatory skin conditions in children. Also known as: Pimecrolimus cream, fluticasone.
This combination suppresses skin inflammation by blocking T-cell activation (pimecrolimus) and reducing inflammatory mediator production (fluticasone).
This combination suppresses skin inflammation by blocking T-cell activation (pimecrolimus) and reducing inflammatory mediator production (fluticasone). Used for Atopic dermatitis in pediatric patients, Inflammatory skin conditions in children.
At a glance
| Generic name | Combination of pimecrolimus and fluticasone |
|---|---|
| Also known as | Pimecrolimus cream, fluticasone |
| Sponsor | Children's Hospital of Philadelphia |
| Drug class | Topical immunosuppressant and corticosteroid combination |
| Target | Calcineurin (pimecrolimus); glucocorticoid receptor (fluticasone) |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Immunology |
| Phase | FDA-approved |
Mechanism of action
Pimecrolimus is a calcineurin inhibitor that prevents T-cell proliferation and cytokine release, while fluticasone is a topical corticosteroid that reduces inflammatory responses. Together, they provide dual anti-inflammatory action for localized skin conditions, particularly in pediatric populations where steroid-sparing approaches are beneficial.
Approved indications
- Atopic dermatitis in pediatric patients
- Inflammatory skin conditions in children
Common side effects
- Application site burning or irritation
- Skin atrophy (with prolonged corticosteroid use)
- Folliculitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination of pimecrolimus and fluticasone CI brief — competitive landscape report
- Combination of pimecrolimus and fluticasone updates RSS · CI watch RSS
- Children's Hospital of Philadelphia portfolio CI
Frequently asked questions about Combination of pimecrolimus and fluticasone
What is Combination of pimecrolimus and fluticasone?
How does Combination of pimecrolimus and fluticasone work?
What is Combination of pimecrolimus and fluticasone used for?
Who makes Combination of pimecrolimus and fluticasone?
Is Combination of pimecrolimus and fluticasone also known as anything else?
What drug class is Combination of pimecrolimus and fluticasone in?
What development phase is Combination of pimecrolimus and fluticasone in?
What are the side effects of Combination of pimecrolimus and fluticasone?
What does Combination of pimecrolimus and fluticasone target?
Related
- Drug class: All Topical immunosuppressant and corticosteroid combination drugs
- Target: All drugs targeting Calcineurin (pimecrolimus); glucocorticoid receptor (fluticasone)
- Manufacturer: Children's Hospital of Philadelphia — full pipeline
- Therapeutic area: All drugs in Dermatology/Immunology
- Indication: Drugs for Atopic dermatitis in pediatric patients
- Indication: Drugs for Inflammatory skin conditions in children
- Also known as: Pimecrolimus cream, fluticasone
- Compare: Combination of pimecrolimus and fluticasone vs similar drugs
- Pricing: Combination of pimecrolimus and fluticasone cost, discount & access